The Lima Lab’s research is concentrated on the development and application of imaging and technology to address scientific and clinical problems involving the heart and vascular system. Specifically, our research is focused on developing magnetic resonance imaging (MRI) contrast techniques to investigate microvascular function in patients and experimental animals with myocardial infarction; functional reserve secondary to dobutamine stimulation and myocardial viability assessed by sodium imaging; and cardiac MRI and computed tomography (CT) program development of techniques to characterize atherosclerosis in humans with cardiovascular or cerebrovascular disease. Current projects include: • The Coronary Artery Risk Development in Young Adults (CARDIA) Study • The MESA (Multi-Ethnic Study of Atherosclerosis) Study • The Coronary Artery Evaluation using 64-row Multidetector Computed Tomography Angiography (CORE64) Study Joao Lima, MD, is a professor of medicine, radiology and epidemiology at the Johns Hopkins School of Medicine.

The Post Lab is involved in the Multi-Ethnic Study of Atherosclerosis (MESA), a collaborative study of the characteristics of subclinical cardiovascular disease (that is, disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. As MESA researchers, we study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Approximately 38 percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent. Participants were recruited from six field centers across the United States, including Johns Hopkins University. Each participant received an extensive physical exam to determine a number of conditions, including coronary calcification, ventricular mass and function, flow-mediated endothelial vasodilation, standard coronary risk factors, sociodemographic factors, lifestyle factors, and psychosocial factors. Selected repetition of subclinical disease measures and risk factors at follow-up visits have allowed study of the progression of disease. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and congestive heart failure; for cardiovascular disease interventions; and for mortality. Wendy S. Post, MD, MS, is an associate faculty, Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, and a professor of medicine.

Dr. Martin's research is focused on rapid generation of new knowledge through clinical studies that can be brought back to the bedside to directly inform the care of patients with advanced lipid disorders and those in need of state-of-the-art comprehensive CV prevention. Members of his lab commit to complete ownership of their project, unwavering pursuit of excellence, and thrive on multidisciplinary teamwork. Active projects include the Very Large Database of Lipids, CASCADE FH Registry, MiCORE (Myocardial infarction, COmbined device, Recovery Enhancement), Google Health Search Trial, and mActive-Smoke. For more information, please visit the Ciccarone Center.

Dr. Sperati’s group focuses on complement mediated kidney disorders, glomerular disease, and renal arterial disease secondary to fibromuscular dysplasia. His team has a particular interest in thrombotic microangiopathies involving the complement system.

The Kathryn Carson Lab investigates ways to improve medical research, particularly in the areas of brain and thyroid cancer, Alzheimer’s disease, atherosclerosis, hypertension, HIV and lupus. Our team seeks to help researchers optimize their studies through better study design, protocol and grant writing, data cleaning and analysis, and publication writing. We work with investigators from a wide range of departments through the Johns Hopkins Institute for Clinical and Translational Research.